


IASLC



**2023 Latin America  
Conference on Lung Cancer**

**JANUARY 25-27, 2023  
MONTEVIDEO, URUGUAY**

**PROGRAM  
BOOK**



**#LALCA23**





**2023 Targeted Therapies  
of Lung Cancer Meeting**

**FEBRUARY 22-25, 2023 | SANTA MONICA, CALIFORNIA**

# REGISTER NOW!

**#TTLC23**  
**[ttlc2023.org](https://ttlc2023.org)**

Learn more about virtual attendance  
at <https://ttlc2023.iaslc.org/>

# Table Of Contents

<b>Welcome Message</b> .....	5
<b>Venue Floorplan</b> .....	8
<b>Program</b> .....	10
WEDNESDAY, JANUARY 25, 2023	
THURSDAY, JANUARY 26, 2023	
FRIDAY, JANUARY 27, 2023	
<b>Poster Listing</b> .....	16
<b>Education Awards</b> .....	20
<b>Industry Supporters &amp; Exhibitors</b> .....	22
<b>General Information</b> .....	25



International Conference Services

## MEETING SECRETARIAT

International Conference Services Ltd. (ICS)

Suite 710, 1201 West Pender Street, Vancouver, BC, Canada, V6E 2V2

Phone: +1 604 681 2153

[www.icsevents.com](http://www.icsevents.com)

## GLOBAL OFFICES

Vancouver, Toronto, Texas, London, Barcelona, Vienna, Tokyo, Singapore

01

# Welcome Message

#LALCA23



# Welcome Message

Dear Colleagues and Friends,

Welcome to the IASLC 2023 Latin America Conference on Lung Cancer taking place January 25 – 27, 2023 at the Radisson Hotel Montevideo Victoria Plaza in Montevideo, Uruguay. Lung Cancer is still the leading cause of death not only in Latin America but worldwide. Building on the success of previous Latin America Conferences on Lung Cancer (LALCA) international and national speakers will discuss the science and advances in the treatment and prevention of lung cancer and thoracic malignancies worldwide and Latin America in particular over the next few days.

With tobacco being the leading cause of morbid-mortality worldwide, the Conference will once again host a Cancer Control Program and Tobacco Forum, scheduled for Wednesday, January 25. The program will discuss important topics in lung cancer such as, but not limited to, development in surgery, radiotherapy innovations, targeted therapy, immunotherapy, and many more. We will continue with the very successful Round Table Discussions providing delegates a very unique opportunity to talk to and discuss directly with international leaders and local experts on specific topics.

We can't wait to see you all!

## LALCA 2023 Meeting Co-Chairs



**Luis Ubillos**  
**MD, PhD**  
LALCA 2023 Co-Chair,  
Uruguay



**Mario Varangot**  
**MD**  
LALCA 2023 Co-Chair,  
Uruguay



**Clarissa Mathias**  
**MD**  
LALCA 2023 Co-Chair,  
Brazil



**Carlos Barrios**  
**MD**  
LALCA 2023 Co-Chair,  
Brazil

## LATAM Group Co-Chairs



**Luis E. Raez**  
**MD, FACP, FCCP**  
LATAM Group Chair,  
United States



**Edgardo S. Santos**  
**MD, FACP**  
LATAM Group Chair,  
United States



**Christian Rolfo**  
**MD, PhD**  
LATAM Group Chair,  
United States

# The current state-of-the-art in lung cancer

Register by 25 January 2023



## IMPORTANT DEADLINES

17 January 2023	Abstract submission
25 January 2023	Early registration
1 March 2023	Late registration

**COPENHAGEN DENMARK**  
**29 MARCH - 1 APRIL 2023**

At this year's innovative LIVE Plus format, you will be able to review the current state-of-the-art in lung cancer therapy, update your knowledge in prevention, screening, detection and much more.

**Register by 25 January 2023 and benefit from advantageous fees.**

## Organisers



## Partners



[esmo.org](http://esmo.org)

03


# Venue Floorplan

#LALCA23



# Venue Floorplan

Radisson Hotel Montevideo Victoria Plaza - 2<sup>nd</sup> Floor



04

# Program

#LALCA23



# Full Program

WEDNESDAY | JANUARY 25, 2023

## 09:00-15:00 IASLC School of Pathology

### Grand Ballroom C2

#### 09:00 Welcome Session

Chairs: Ignacio Wistuba, United States, Maria Arcila, United States

## Principles and Methods: Surgical Pathology

Chair: Ignacio Wistuba, United States

#### 09:05 Maximizing Tissue Utilization

Christina Fernandez, Chile

#### 09:25 Choosing Best Tissue for Molecular Studies

Fabio Tavora, Brazil

#### 09:45 Immunohistochemical Studies and FISH

Sergio Sanchez, México

#### 10:05 Discussion

## Principles and Methods: Molecular Track – Tumor Tissue Testing

Chair: Ignacio Wistuba, United States

#### 10:45 Review of Guidelines

Mercedes Liliana Dalurzo, Argentina

#### 11:05 Molecular Studies – Technology

Isabela Werneck da Cunha, Brazil

#### 11:25 Single Gene vs Panel vs NGS

Valeria Denninghoff, Argentina

#### 11:45 Discussion

## 12:00 - 13:00 Lunch Break

## Principles and Methods: Molecular Track – Liquid Biopsy Testing

Chair: Maria Arcila, United States

#### 13:00 Plasma Testing vs Tissue

Christian Rolfo, United States

#### 13:20 Other Liquid Biopsies – Body Fluids and Their Value

Maria Arcila, United States

#### 13:40 Discussion

## Applications - Case studies - Outlining the Latin American Experience

Chair: Maria Arcila, United States

#### 14:00 Outline Challenges in Interpreting PDL1 Stains

Fabio Tavora, Brazil

#### 14:10 Outline Challenges in Working with very Minimal Tumor Tissue – Low Tumor Content and Low Tissue Content

Ricardo Armisen, Chile

#### 14:20 Outline the Use of Cell Free DNA – Limitations, Benefits

Sergio Sanchez, México

#### 14:30 Outline the Role of Evolving Biomarkers

Maria Arcila, United States

#### 14:40 Discussion

January 25 – 27, 2023 | Montevideo, Uruguay

Program Book | IASLC 2023 Latin America Conference on Lung Cancer

## 09:15-15:00 IASLC School of Thoracic Oncology

### Grand Ballroom C1

#### 09:00 Welcome Session

Chairs: Norma Graciela Pilnik, Argentina, Edgardo Santos, United States, Luis Ubillos, Uruguay

#### 09:15 Knowing IASLC: Why I Need to Be Part?

Heather Wakelee, United States

#### 09:30 LATAM Activities

Luis Ubillos, Uruguay

#### 09:45 Clinical Research in Lung Cancer: Gaps and Opportunities

Andres Cardona, Colombia

#### 10:15 Planning a Career in Lung Cancer – Academia Practice

Norma Graciela Pilnik, Argentina

#### 10:40 Planning a Career in Lung Cancer – Private Practice

Luis Corrales, Costa Rica

#### 11:00 How to Become a Translational Physician

Christian Rolfo, United States

#### 11:20 Clinical Research in the Community Setting

Luis Corrales, Costa Rica

#### 11:35 Publish Your Research: Knowing the Process

Karen Kelly, United States

## 12:00 - 13:00 Lunch Break

#### 13:00 Updating Your CV and Personal Statement

Luis Ubillos, Uruguay

#### 13:15 Establishing a Basic Lab: Minimal Requirements

Rafael Rosell, Spain

#### 13:30 Partnership Academia – Pharma: How to Navigate?

Edgardo Santos, United States

#### 13:45 Radiation and Medical Oncologists Doing Research Together in LATAM: A Mirage?

Beatriz Amendola, United States

#### 14:00 Building A Strong Thoracic Program: The Beauty of Multidisciplinary Team

Ricardo Sales dos Santos, Brazil

#### 14:15 A Grant: How to Write and Get it?

Rafael Rosell, Spain

#### 14:35 Wrap up and Adjourn

## 15:00-16:00 Living Room

### Grand Ballroom C2

#### 15:00 Diagnosing and Treating Lung Cancer in Latin America

Luis E. Raez, United States

## 16:00-17:00 Cancer Control Program and Tobacco Forum

### Grand Ballroom C1

Chairs: Denisse Bretel, Perú, Elizabeth Ravera, United States

#### 16:00 Implementing Interventions for Tobacco Control: Research-based Policies

Carlos Gil Ferreira, Brazil

#### 16:15 Importance of Smoking Cessation in the Treatment of Lung Cancer Patient

Lucia Viola, Colombia



# WEDNESDAY | JANUARY 25, 2023

## 16:30 Framework Convention in WHO in LATAM

Paulo César Correa, Brazil

## 16:45 Discussion

## 17:00-18:00 Lung Cancer Screening

### Grand Ballroom C2

Chairs: Gelenis Domingo, United States, Luis Corrales, Costa Rica

## 17:00 Establishing Lung Cancer Screening as Standard of Care

Luis Corrales, Costa Rica

## 17:15 Incidental Pulmonary Programs as a Complement for Lung Cancer Screening

Lucia Viola, Colombia

## 17:30 Lung Cancer Screening in Latin America: Challenges and Progress

Ricardo Sales dos Santos, Brazil

## 17:45 Discussion

## 18:00-18:45 IASLC/LATAM General Meeting

### Grand Ballroom C1

Chairs: Luis E. Raez, United States, Christian Rolfo, United States, Edgardo Santos, United States

## 19:00-19:30 Opening Ceremony

### Grand Ballroom C1

Chairs: Carlos Barrios, Brazil, Clarissa Mathias, Brazil, Luis Ubillos, Uruguay, Mario Varangot, Uruguay

## 19:30-20:30 Welcome Reception

### Grand Ballroom C3

# THURSDAY | JANUARY 26, 2023

## 08:30-09:30 SS.01: Diagnostic Imaging Innovation

### Grand Ballroom C1

Chair: Margarita Garcia Fontes, Uruguay

## 08:30 EBUS and Navigation System to Yield a Diagnosis

Lucia Viola, Colombia

## 08:45 Robotic Bronchoscopy in Lung Cancer

Francisco Tarrazzi, United States

## 09:15 Discussion

## 08:30-09:30 SS.02: Early Career Session & Research Vision

### Grand Ballroom C2

Chairs: Denisse Bretel, Perú, Christian Caglevic, Chile

## 08:30 How to Write a Manuscript and a Research Grant

Carlos Gil Ferreira, Brazil

## 08:45 How to Incorporate Research in Latin America

Carlos Barrios, Brazil

## 09:00 The Role of Medical School to Promote Basic and Clinical Research

Norma Graciela Pilnik, Argentina

## 09:15 Discussion

## 09:30 - 10:30 Networking Break and Poster Viewing | Grand Ballroom C3

*Refreshments will be provided*

## 10:30-11:30 SS.03: Lung Cancer Pathology in the Era of Targeted Therapy

### Grand Ballroom C1

Chairs: Mercedes Liliانا Dalurzo, Argentina

## 10:30 Tissue Quality Control for Molecular Testing

Maria Arcila, United States

## 10:45 New Massive Parallel Sequencing Platforms (NGS) Versus Tailored Panels (ddPCR)

Ignacio Wistuba, United States

## 11:00 Molecular Markers in SQCC

Alberto Chiappori, United States

## 11:15 Discussion

## 10:30-11:30 SS.04: Novel Diagnostic and Prognostic Markers

### Grand Ballroom C2

Chairs: Edgardo Santos, United States, Tannia Soria Samaniego, Ecuador

## 10:30 The Future of ctDNA

David R. Gandara, United States

## 10:45 Moving NGS in Liquid Biopsies to the Front Lines and Assessing Resistance Genomic Aberrations

Luis E. Raez, United States

## 11:00 New Technologies for Liquid Biopsies (Methylation, Exosomes, ECVs and CTCs)

Christian Rolfo, United States

## 11:15 Discussion

## 11:45-12:45 SS.05: New Developments in Surgery

### Grand Ballroom C1

Chairs: Edgar Amorin, Perú, Ricardo Sales dos Santos, Brazil

## 11:45 Invasive Mediastinal Staging and Navigation (Mediastinoscopy, EBUS, EUS)

Ricardo Mingarini Terra, Brazil

## 12:00 VATS, Robot-Assisted or Thoracotomy for Lung Cancer Surgery

Ricardo Sales dos Santos, Brazil

## 12:15 Sub-lobar Resection for Stage I NSCLC

Francisco Tarrazzi, United States

## 12:30 Discussion

## 11:45-12:45 **SS.06: Adjuvant Therapy in the Molecular Era**

### Grand Ballroom C2

Chairs: Carlos Gil Ferreira, Brazil, Ticiana Leal, United States

- 11:45 Prognostic and Predictive Markers for Adjuvant Therapy NSCLC**  
David Carbone, United States
- 12:00 Targeted Agents in the Adjuvant Setting**  
Edgardo Santos, United States
- 12:15 Immunotherapy in Lung Cancer Adjuvant Setting**  
Claudio Martin, Argentina
- 12:30 Discussion**

## 13:00 - 14:00 Lunch Break | Grand Ballroom C3 *Refreshments will be provided*

## 13:00-14:00 Industry Symposium Sponsored by Caris Life Sciences: Upfront Broad Profiling Improves Outcomes In NSCLC

### Grand Ballroom C1

- 13:00 Welcome**  
Vasanti Natarajan, Switzerland
- 13:05 Upfront Broad Profiling Improves Outcomes in NSCLC**  
Luis Raez, United States
- 13:30 Case Discussion**  
Edgardo Santos, United States
- 13:50 Q&A with panel and audience**

## 13:00-14:00 Industry Symposium Sponsored by Varian: Truebeam Technology for the Treatment of Lung Tumors

### Grand Ballroom C2

- 13:00** Beatriz Amendola, United States

## 14:15-15:15 **SS.07: Radiotherapy Innovations**

### Grand Ballroom C1

Chair: Arthur Accioly Rosa, Brazil

- 14:15 SBRT for Oligometastatic Disease**  
Beatriz Amendola, United States
- 14:30 Role of SBRT in Early Stage NSCLC**  
Gustavo Sarria, Perú
- 14:45 High Technology in Radiation Therapy, Potential Indications, and Benefits in Lung Cancer**  
Ana Botero, United States
- 15:00 Discussion**

## 14:15-15:15 **SS.08: Combined Modality Therapy**

### Grand Ballroom C2

Chairs: Gustavo Ferraris, Argentina, Tannia Soria Samaniego, Ecuador

- 14:15 Combining Radiation Therapy with Targeted Therapy in Oligometastatic Disease**  
Andres Cardona, Colombia

- 14:30 Radiation Therapy Combined With Immunotherapy for Unresectable NSCLC**  
Clarissa Mathias, Brazil
- 14:45 Radiation Therapy Combined with Immunotherapy as Neoadjuvant Approach**  
Ticiana Leal, United States
- 15:00 Discussion**

## 15:15 - 16:15 Networking Break and Poster Viewing | Grand Ballroom C3

*Refreshments will be provided*

## 16:15-17:15 **SS.09: Poster Discussion #1**

### Grand Ballroom C1

Chairs: Luis Mas, Perú, Heather Wakelee, United States

- 16:15 PD.01.01 - Acquired EGFR Resistant Mutations and Co-mutations in Tumors Of Non-small Cell Lung Cancer Patients Treated With Tyrosine Kinase Inhibitors (TKI)**  
Luis E. Raez, United States
- 16:20 PD.01.02 - Novel MicroRNAs Identified in Lung Cancer and Associated With Malignant Metabolism (In Silico)**  
Ana Laura Seneda, Brazil
- 16:25 PD.01.03 - Genomic Landscape of Primary-Resistance to Osimertinib among Hispanic Patients With EGFR-Mutant Non-Small-Cell Lung Cancer: Results of an Observational Longitudinal-Cohort Study**  
Andres Cardona, Colombia
- 16:30 Posters Discussion**  
Rafael Rosell, Spain
- 16:40 PD.01.04 - Rate of Pathogenic Germline Variants Detected in ctDNA Among Patients With Non-Small Cell Lung Cancer in a Predominantly Hispanic/Latinx Population**  
Samuel Kareff, United States
- 16:45 PD.01.05 - Expanding Lung Cancer Education and LungMATCH, a Treatment and Trial Navigation Program, in a Culturally Sensitive Way with Nuestra Gente**  
Renee Botello, United States
- 16:50 Posters Discussion**  
Paul Bunn, United States
- 17:00 Discussion**

## 16:15-17:15 **SS.10: Poster Discussion #2**

### Grand Ballroom C2

Chairs: Oscar Arrieta, México, Tannia Soria Samaniego, Ecuador

- 16:15 PD.02.01 - High Extracellular Vesicle TGF- & PD-L1 Predict Poor Outcomes in Patients With Non-small Cell LungCancer Undergoing Immune-Checkpoint Inhibitors**  
Diego De Miguel Perez, United States
- 16:20 PD.02.02 - Lung TS: A New 6-Gene Signature for Prediction of Response to Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer Patients**  
Letícia Ferro Leal, Brazil

# THURSDAY | JANUARY 26, 2023

- 16:25 PD.02.03 - Alterations in the Immune Profile of LUSC and LUAD Detected by a Neural Network May Reveal New Immunotherapy Targets**  
Iael Weissberg, Brazil
- 16:30 Posters Discussion**  
David R. Gandara, United States
- 16:40 PD.02.04 - A Prognostic Value of 3 Gene Sets for Ever-Smokers With Non-small Cell Lung Cancer From Brazil**  
Isabella Lemuqui Tegami, Brazil
- 16:45 PD.02.05 - EGFR Exon 20 Insertion Mutations in a Brazilian Lung Cancer Cohort: Challenges for the Identification and Clinical Features**  
Izabella Santos Negreiros, Brazil
- 16:50 PD.02.06 - Intensified Chemo-Immuno-Radiotherapy With Durvalumab for Stage Iii NSCLCS: A Brazilian Single Arm Phaseli Study - Pacific Brazil (LACOG 2218)**  
William Nassib William Junior, Brazil
- 16:55 Posters Discussion**  
David Carbone, United States
- 17:05 Discussion**



# FRIDAY | JANUARY 27, 2023

## 07:30-08:30 IASLC Women in Thoracic Oncology

### Grand Ballroom C2

Chairs: Karen Kelly, United States, Clarissa Mathias, Brazil, Heather Wakelee, United States

- 07:30 Opening Remarks**  
Karen Kelly, United States
- 07:35 How can We Inspire Other Women to Become Leaders?**  
Heather Wakelee, United States
- 07:50 Empowering Women- What are We Achieving?**  
Clarissa Mathias, Brazil
- 08:05 Panel Discussion**  
Clarissa Mathias, Brazil  
Heather Wakelee, United States  
Karen Kelly, United States  
Lucia Viola, Colombia

## 08:30-09:30 SS.11: New Developments in Targeted Therapy of Other Thoracic Malignancies

### Grand Ballroom C1

Chairs: Luis Mas, Perú, Eduardo Richardet, Argentina

- 08:30 Is There a Targeted Therapy for SCLC**  
William Nassib William Junior, Brazil
- 08:45 Mesothelioma: Challenges in Diagnosis and Therapeutic Outlook**  
Gelenis Domingo, United States
- 09:00 Biological Insights and Novel Therapy for Malignant Thymoma**  
Luis Corrales, Costa Rica
- 09:15 Discussion**

## 09:45-10:45 SS.12: Presidential Symposium

### Grand Ballroom C1

Chairs: Luis Ubillos, Uruguay, Mario Varangot, Uruguay

- 09:45 PSP.01 - Disruptive and Truncating TP53 Mutations Are Frequent in Lung Adenocarcinoma Patients With African Ancestry and Show Worse Prognosis**  
Rodrigo de Oliveira Cavagna, Brazil
- 09:55 PSP.02 - Using DNA Next-Generation Sequencing in blood to Guide Therapy for Newly Diagnosed Stage IV Non-Small Cell Lung Cancer (NSCLC) Patients**  
Luis E. Raez, United States
- 10:05 PSP.03 - 12-Gene Expression Signature: A Potential Key for Predicting Prognosis and Benefit to ACT for Resectable NSCLC Patients**  
Aléxia Siqueira, Brazil
- 10:15 Presidential Symposium Discussion**  
David R. Gandara, United States
- 10:30 Discussion**

## 10:45 - 11:45 Networking Break and Poster Viewing | Grand Ballroom C3

*Refreshments will be provided*

## 11:45-12:45 Round Table Discussions

### Grand Ballroom C1

Chairs: Clarissa Baldotto, Brazil, Eduardo Richardet, Argentina

#### Table Discussion 1 - Early Stage Lung Cancer: Adjuvant Treatment

Carlos Barrios, Brazil  
Norma Graciela Pilnik, Argentina  
Edgardo Santos, United States

## Table Discussion 2 - Novel Approaches in Surgery (Robotic Surgery, VATS, Navigation System)

Ricardo Sales dos Santos, Brazil

Francisco Tarrazzi, United States

Ricardo Mingarini Terra, Brazil

## Table Discussion 3 - Treatment of Wild Type Lung Cancer Tumors (First and Second Line)

Paul Bunn, United States

Carlos Carracedo, Perú

## Table Discussion 4 - Therapy of Tumors Carrying EGFR Mutations

Luis Corrales, Costa Rica

Karen Kelly, United States

Rafael Rosell, Spain

## Table Discussion 5 - ALK Positive Tumors: Therapies

Rossana Ruiz, Perú

Ticiana Leal, United States

Gelenis Domingo, United States

## Table Discussion 6 - How to Study Molecular Biology and Tumor Markers

Fred R. Hirsch, United States

Ignacio Wistuba, United States

## Table Discussion 7 - New Molecules and Therapies for Lung Cancer

Claudio Martin, Argentina

David R. Gandara, United States

Oscar Arrieta, México

## Table Discussion 8 - Oligometastatic Lung Cancer

Beatriz Amendola, United States

Ana Botero, United States

William Nassib William Junior, Brazil

## Table Discussion 9 - Diagnosis and Staging in Lung Cancer

Lucia Viola, Colombia

Luis Ubillos, Uruguay

## Table Discussion 10 - Locally Advanced Lung Cancer

Luis Mas, Perú

## Table Discussion 11 - Immunotherapy in Non-small Lung Cancer in Early Stage

Clarissa Mathias, Brazil

Luis E. Raez, United States

## Table Discussion 12 - Liquid Biopsy

Christian Rolfo, United States

Maria Arcila, United States

## Table Discussion 13 - Uncommon Oncology Drivers: ROS1, BRAF, NTRK, MMR, RET

Alberto Chiappori, United States

Andres Cardona, Colombia

## Table Discussion 14 - Small Cell Lung Cancer

Elizabeth Ravera, United States

Clarissa Baldotto, Brazil

Diego Touya, Uruguay

**13:00 - 14:00 Lunch Break I Grand Ballroom C3**  
*Refreshments will be provided*

## 14:15-16:00 SS.13: Targeted Therapy & Angiogenesis

### Grand Ballroom C1

Chairs: Oscar Arrieta, México, Carlos Carracedo, Perú

#### 14:15 EFGR Exon 20 and Other Uncommon Mutations

Heather Wakelee, United States

#### 14:25 ALK Genomic Aberrations

Fred R. Hirsch, United States

#### 14:35 cMET/BRAF/HER-2/3 Inhibitors

Paul Bunn, United States

#### 14:45 ROS-1 Translocations

Christian Rolfo, United States

#### 14:55 NTRK and NRG1 Fusion Proteins

Luis E. Raez, United States

#### 15:05 New Insights of EGFR Inhibition and Mechanisms of TKI Resistance

Rafael Rosell, Spain

#### 15:15 EGFR/ALK TKIs with Central Nervous System Penetration

Claudio Martin, Argentina

#### 15:25 KRAS and STK11 Mutations and Co-Mutations

Alberto Chiappori, United States

#### 15:35 Discussion

## 14:15-16:00 SS.14: Immunotherapy

### Grand Ballroom C2

Chairs: Luis Mas, Perú, Clarissa Baldotto, Brazil

#### 14:15 Front Line Immunotherapy Only for NSCLC: What is New?

Luis Corrales, Costa Rica

#### 14:25 Immunotherapy Combinations No More Chemotherapy

Ticiana Leal, United States

#### 14:35 Immunotherapy Resistance and Agents

David R. Gandara, United States

#### 14:45 Molecular Markers for Immunotherapy

Andres Cardona, Colombia

#### 14:55 Immunotherapy in SQCC: The Time Has Arrived

Luis Mas, Perú

#### 15:05 Small Cell Lung Cancer Immunotherapy

William Nassib William Junior, Brazil

#### 15:15 Immunotherapy and Oligometastatic Disease

Karen Kelly, United States

#### 15:25 Discussion

## 16:05-16:30 Closing Ceremony with Education Awards Presentations

### Grand Ballroom C1

Chairs: Carlos Barrios, Brazil, Luis Ubillos, Uruguay, Mario Varangot, Uruguay

#### Education Awards Presentations Introducing LALCA 2024

Andres Cardona, Colombia

Tannia Soria Samaniego, Ecuador

Lucia Viola, Colombia

05

# Poster Listing

#LALCA23



# Poster Listing

## *PP.01 - PP.17: Advanced NSCLC*

### **PP.01 - Study Evaluating Alectinib Pharmacokinetics in the Hispanic Population With Advanced ALK-Rearranged Non-small-Cell Lung Cancer**

Oscar Arrieta, México

### **PP.02 - Tyrosine Kinase Inhibitor (TKI) Real-World Use in Epidermal Growth Factor Receptor Mutated (EGFRm) Advanced Non-small Cell Lung Cancer (NSCLC) Patients**

Lucía Kaminszczyk, Argentina

### **PP.03 - Gender Differences in Lung Cancer in Chile**

Diego Carrillo, Chile

### **PP.04 - EGFR Structure-Based Classification and Presence of Commutations in Peruvian Patients With Advanced Lung Cancer**

Luis Mas, Perú

### **PP.05 - Access to Genomic Testing and Targeted Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC): A Single-Institution Study**

Berenice Freile, Argentina

### **PP.06 - Real-World Study of EGFR-TKIs Combined With Radiotherapy in Patients With Brain Metastases From Non-small Cell Lung Cancer**

Yi Liu, China

### **PP.07 - Preliminary Results of a Western Mexican Cohort of Metastatic NSCLC and frequency of ALK, EGFR and PD-L1**

Mauricio de Jesús Mora Pineda, México

### **PP.08 - Analysis of the Status of Tumor-Infiltrating Lymphocytes (TILS) In Patients With NSCLC**

Eduardo Richardet, Argentina

### **PP.09 - Neutrophil Lymphocyte Ratio as a Prognostic Factor in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)**

Eduardo Richardet, Argentina

### **PP.10 - Role of the Neutrophil-Lymphocyte Relationship in Patients With Advanced NSCLC Treated With Immunotherapy**

Eduardo Richardet, Argentina

### **PP.11 - Effectiveness of Ramucirumab Plus Docetaxel for Advanced Non-Small Cell Lung Cancer Patients: a Cohort of 93 Patients**

Isabella Favato Barcelos, Brazil

### **PP.12 - Access to Molecular Testing and Factors to Implement Targeted Therapy in a Brazilian Public Health Service**

Luma Princess Schneider, Brazil

### **PP.13 - Aptamers as Novel Diagnostic Tools for Lung Cancer Detection**

Yuli Yohana Serna Torres, Brazil

### **PP.14 - Real World Data of Patients $\geq$ 80 Years Old With Metastatic NSCLC: Evaluation of an Underrepresented Population in Clinical Trials**

Filipe Visani, Brazil

### **PP.15 - Efficacy and Safety of PD-1 Monoclonal Antibody in the Real World**

Yaning Zhu, China

### **PP.16 - Evaluation of Pathogenicity and in Silico Analysis of HERC2 Variants in Non-Small Cell Lung Cancer**

Letícia Ferro Leal, Brazil

### **PP.17 - Stereotactic Ablative Radiotherapy in Oligometastatic Pulmonary Disease. First Institutional Experience**

Gustavo Ferraris, Argentina

## *PP.18 - PP.26: Biology and Pathogenesis, Pathology*

### **PP.18 - Cellular Foundations of Radiotherapy Protocols Frequently Used in Pulmonary Pathology**

Gustavo Ferraris, Argentina

### **PP.19 - Methylation Profile of Non-Small Cell Lung Cancer of Brazilian Patients**

Letícia Ferro Leal, Brazil

### **PP.20 - Concordance of Actionable Mutations in Liquid Biopsies and Matched Tumor Tissue of Brazilian Non-small Cell Lung Cancer (NSCLC)**

Letícia Ferro Leal, Brazil

# Poster Listing

## **PP.21 - Genomic Landscape of Admixed Non-small Cell Lung Cancer: A Series of Brazilian Single-Center**

Letícia Ferro Leal, Brazil

## **PP.22 - Mutational Profile of Never-Smoker Patients With Lung Adenocarcinoma From a Single-Center in Brazil**

Rodrigo de Oliveira Cavagna, Brazil

## **PP.23 - GALNT13 Detection in Liquid Biopsy in Non-Small Cell Lung Cancer (NSCLC) Patients**

Eugenia Fernandez Armua, Uruguay

## **PP.24 - High Correlation With KRAS and PDL-1 in Lung Adenocarcinoma of a Single Institution**

Bruna Motke, Brazil

## **PP.25 - Quality of the Tissue Sample in the Determination of the Molecular Profile of Lung Cancer. Our Experience**

Norma Graciela Pilnik, Argentina

## **PP.26 - Immunoexpression of 4 Different PD-L1 Clones in NSCLC Cases, a Comparative Study From Northeastern Brazil**

Fabio Tavora, Brazil

## **PP.27 - PP.36: Early Stage NSCLC (Stage I - III)**

## **PP.27 - Clinical Outcomes of Stage III Non-small Cell Lung Cancer Patients Treated With Radical Radiotherapy in a Institution in Brazil**

Denize Bodnar, Brazil

## **PP.28 - Underutilization of Systemic Therapy in Patients Undergoing Pneumonectomy: A Missed Opportunity for Survival**

Jorge Humberto Rodriguez Quintero, United States

## **PP.29 - Management of Lung Cancer During the COVID-19 Pandemic: Experience of a High Complexity Center in Medellin-Colombia**

Ricardo Zapata Gonzalez, Colombia

## **PP.30 - Comparing the Most Influential Publications on Robotic-Assisted Pulmonary Lobectomy and on Robotic-Assisted Pulmonary Segmentectomy**

Eric Toloza, United States

## **PP.31 - Marital Status Shows No Protective Effect on Perioperative Outcomes After Robotic-Assisted Pulmonary Lobectomy**

Eric Toloza, United States

## **PP.32 - Postoperative Serum Magnesium Levels and Outcomes Following Robotic-Assisted Pulmonary Lobectomy**

Eric Toloza, United States

## **PP.33 - Effect of Age on Incidences of Peri-Operative Outcomes after Robotic-Assisted Video-Thoracoscopic Pulmonary Lobectomy**

Allison Dumitriu Carcoana, United States

## **PP.34 - Impact of Cardiac Comorbidities on Perioperative Outcomes After Robotic-Assisted Pulmonary Lobectomy**

Allison Dumitriu Carcoana, United States

## **PP.35 - Preoperative Blood-Urea-Nitrogen-to-Serum-Albumin Ratio Is Not a Predictor of Worse Outcomes After Robotic-Assisted Pulmonary Lobectomy for Lung Cancer**

Allison Dumitriu Carcoana, United States

## **PP.36 - Thoracoscopic Limited Resection in Lung Adenocarcinoma, 4 Years Disease-Free Survival**

Emmanuel Peña Gomez Portugal, México

## **PP.37 - PP.40: SCLC, Mesothelioma, Thymoma**

## **PP.37 - Thymic Neuroendocrine R0 Surgery**

Emmanuel Peña Gomez Portugal, México

## **PP.38 - Unusual Location of Thymic Carcinoma and It's Surgical Management**

Emmanuel Peña Gomez Portugal, México

## **PP.39 - Helical Tomotherapy for Primary and Secondary Malignant Pleural Tumors**

Marija Jankova, Bulgaria

## **PP.40 - Phase II Clinical Study: Whole-Brain Radiotherapy Plus Sequential or Simultaneous Integrated Boost for the Treatment of Brain Metastases in NSCLC**

Dai Yuan Ma, China

# Poster Listing

## **PP.41 - PP.44: Immunotherapy**

### **PP.41 - Novel Synthetic Extracellular Vesicles as a Chemotherapeutic Carrier for Potential Lung Cancer Treatment**

Javiera Carrasco-Rojas, Chile

### **PP.42 - Phase 1 Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced NSCLC**

Byoung Chul Cho, Korea

### **PP.43 - Retrospective Analysis of Serum Parameters in Patients Treated With Check-Point Inhibitors in 2AND Line for Advance Non-small-Cell Lung Cancer**

Pablo Flores Paco, Spain

### **PP.44 - Immune-Checkpoint Inhibitors: Biomarkers to Predict Response to Immunotherapy in Non-small Cell Lung Cancer Patients**

Katiane Tostes, Brazil

## **PP.45 - PP.46: Nursing & Allied Health & Patient Advocacy & Supportive Care**

### **PP.45 - Understanding Therapeutic Trajectories of Adults With Lung Cancer in Chile: A Multi-Methods Study of Time to Diagnosis and Perceived Experience**

Carla Campaña, Chile

### **PP.46 - The Impact of Multidisciplinary Teams on the Diagnosis and Staging of Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis**

Gilberto Castro Junior, Brazil

## **PP.47 - PP.53: Prevention, Early Detection, Epidemiology and Tobacco Control**

### **PP.47 - Lacking Representation of Hispanics in Lung Cancer Screening Trials**

Caio Heleno, United States

### **PP.48 - Breakthrough SARS-CoV-2 Infection and COVID-19 Disease Severity in Lung Cancer Patients**

Diego De Miguel Perez, United States

### **PP.49 - Use of Ultrasound Guidance in Thoracic Surgery Biopsies in Lung Cancer**

Macarena Muto, Uruguay

### **PP.50 - Implementation of an Institutional Lung Cancer Screening Program Using Low-Dose Computed Tomography in Argentina**

María Delfina Peralta Tanco, Argentina

### **PP.51 - Cost-Effectiveness Study of Lung Cancer Screening in Uruguay (UY-LUNGS)**

Virginia Rodriguez Sande, Uruguay

### **PP.52 - Current status of Lung Cancer Screening in Latin America**

Lucia Viola, Colombia

### **PP.53 - Lung Cancer in Peru: A Disease of Never Smokers**

Rossana Ruiz, Perú






06



# Education Awards



#LALCA23



# Education Awards

## Congratulations to the LALCA 2023 Education Award Winners!

Award Winners will be presented with their award during the **Closing Ceremony** on **Friday, January 27** from **16:05 - 16:30** in **Grand Ballroom C1**.

### Diego De Miguel Perez

Icahn School Of Medicine At Mount Sinai New York, United States

**PD.02.01:** High Extracellular Vesicle TGF- $\beta$  & PD-L1 Predict Poor Outcomes in Patients With Non-small Cell Lung Cancer Undergoing Immune-Checkpoint Inhibitors

SS.10: Poster Discussion #2

**Thursday, January 26 | 16:15 - 17:15**

**Grand Ballroom C2**

### Ana Laura Seneda

Faculty Of Medicine, São Paulo State University (UNESP), Brazil

**PD.01.02:** Novel MicroRNAs Identified in Lung Cancer and Associated With Malignant Metabolism (In Silico)

SS.09: Poster Discussion #1

**Thursday, January 26 | 16:15 - 17:15**

**Grand Ballroom C1**

### Aléxia Siqueira

Molecular Oncology Research Center, Barretos Cancer Hospital, Brazil

**PSP.03:** 12-Gene Expression Signature: A Potential Key for Predicting Prognosis and Benefit to ACT for Resectable NSCLC Patients

SS.12: Presidential Symposium

**Friday, January 27, 09:45 - 10:45**

**Grand Ballroom C1**

### Samuel Kareff

University Of Miami Sylvester Comprehensive Cancer Center/ Jackson Memorial Hospital, United States

**PD.01.04:** Rate of Pathogenic Germline Variants Detected in ctDNA Among Patients With Non-Small Cell Lung Cancer in a Predominantly Hispanic/Latinx Population

SS.09: Poster Discussion #1

**Thursday, January 26 | 16:15 - 17:15**

**Grand Ballroom C1**

### Rodrigo de Oliveira Cavagna

Barretos Cancer Hospital, Brazil

**PSP.01:** Disruptive and Truncating TP53 Mutations Are Frequent in Lung Adenocarcinoma Patients With African Ancestry and Show Worse Prognosis

SS.12: Presidential Symposium

**Friday, January 27, 09:45 - 10:45**



**Grand Ballroom C1**



07



**Industry  
Supporters  
& Exhibitors**



#LALCA23



# Industry Supporters and Exhibitors

The IASLC 2023 Latin America Conference on Lung Cancer would like to thank the following companies for their support:



## Supporters Lists

### BRONZE LEVEL



# Industry Supporters and Exhibitors

EXHIBITOR	DESCRIPTION
	<p><b>Caris Life Sciences®</b> is the leading molecular science and technology company developing innovative solutions to revolutionize healthcare and improve patient outcomes. With a primary focus on cancer, Caris' suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps patients, physicians and researchers better detect, diagnose and treat patients.</p> <p><a href="http://www.carislifesciences.com">www.carislifesciences.com</a></p>
	<p>At <b>Janssen</b>, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson &amp; Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart.</p> <p><a href="http://www.janssenpro.com">www.janssenpro.com</a></p>
	<p><b>Seagen</b> is a global biotechnology company that discovers, develops, and commercializes medicines for cancer. The company has a pipeline of therapies at various stages of preclinical testing, clinical testing, and development. For more information visit <a href="http://www.seagen.com">www.seagen.com</a></p>
	<p>At <b>Varian, a Siemens Healthineers company</b>, we envision a world without fear of cancer. For more than 70 years, we have developed, built and delivered innovative cancer care technologies and solutions for our clinical partners around the globe to help them treat millions of patients each year. With an Intelligent Cancer Care approach, we are harnessing advanced technologies like artificial intelligence, machine learning and data analytics to enhance cancer treatment and expand access to care. Our 11,000 employees across 70 locations keep the patient and our clinical partners at the center of our thinking as we power new victories in cancer care. Because, for cancer patients everywhere, their fight is our fight. For more information, visit <a href="http://www.varian.com">www.varian.com</a> and follow @VarianMedSys on Twitter</p>
	<p><b>The International Association for the Study of Lung Cancer (IASLC)</b> is the only global network dedicated to the study and eradication of lung cancer and other thoracic malignancies. Since its founding in 1974, the association's membership has grown to more than 8,000 lung and thoracic cancer specialists from all disciplines and more than 100 countries. By hosting global conferences, funding cutting-edge research, and educating the health care community and the public about thoracic cancers, the IASLC works to alleviate the burden lung cancer places on patients, families, and communities.</p>

04

# General Information

#LALCA23



# General Information

## HEALTH & SAFETY MEASURES

LALCA 2023 will be hosted as an in-person meeting. The health and safety of all our stakeholders are of the utmost importance. Although we are excited to welcome you to LALCA 2023, all necessary precautions will be taken to ensure a safe environment throughout the Conference. The following measures will be put in place to achieve this commitment (applicable to all staff, delegates, exhibitors, sponsors, and guests):



### VACCINATION POLICY

IASLC recommends that all in-person attendees are fully vaccinated against COVID-19 by the time of the Conference. Fully vaccinated refers to completing the approved first 2 vaccines, as per the guidelines of their country of residence. IASLC will, however, not require proof of vaccination prior or during the Conference.



### MASKS AND FACE COVERINGS

Masks will be encouraged to be worn at LALCA 2023. By attending, you agree that:

- You have no COVID-19 symptoms
- If during your attendance you develop any COVID-19 symptoms, you will immediately:
  - Self-isolate;
  - Comply with all local/national government restrictions; and
  - Inform the LALCA 2023 Conference Secretariat by email ([lalca2023-registration@icsevents.com](mailto:lalca2023-registration@icsevents.com)).

IASLC and their suppliers will, in their best effort, provide a safe environment to meet. It is expected that all participants will follow the measures to help reduce the risk.

**Please note:** There will be no on-site testing facility available at LALCA 2023.



### WI-FI

Network: LALCA2023  
Password: LALCA2023

## OPENING HOURS

### Registration Desk

 **Foyer, 2nd Floor**

Wednesday, January 25	<b>08:00 - 19:30</b>
Thursday, January 26	<b>08:00 - 16:30</b>
Friday, January 27	<b>07:00 - 14:30</b>

### Poster Viewing & Networking

 **Grand Ballroom C3, 2nd Floor**

Thursday, January 26	<b>09:30 - 10:30</b> <b>15:30 - 16:30</b>
Friday, January 27	<b>10:45 - 11:45</b>

### Exhibit Hours

 **Grand Ballroom C3, 2nd Floor**

Wednesday, January 25	<b>19:30 - 20:30</b> <b>Welcome Reception</b>
Thursday, January 26	<b>09:30 - 16:30</b>
Friday, January 27	<b>10:30 - 14:00</b>




## ACCESS/SECURITY

Attendees are requested to wear their name badges at all times in order to participate in the Scientific Sessions and Exhibition. A 50 USD fee applies for any name badge reprints due to lost name badges.



## LOST AND FOUND / MESSAGES

Lost and found items should be returned / claimed at the Registration Desk.



# 2023 World Conference on Lung Cancer

SEPTEMBER 9-12, 2023 | SINGAPORE

# Save the Date!

**Join us for WCLC 2023 in Singapore!**

Abstract Submissions will open in January 2023.

Showcase your research and contribute to discussions that will shape the future of treatments in lung cancer and thoracic malignancies.

## CONNECT WITH US



@IASLC



facebook.com/IASLC



@iaslungcancer



linkedin.com/IASLC



IASLC

# #WCLC23

WLCL2023.IASLC.org

# IASLC 2022-23

## MEETINGS SCHEDULE

### IASLC 2023 Targeted Therapies of Lung Cancer Meeting

February 22-25, 2023  
Santa Monica, California  
#TTLC23

### IASLC 2023 Hot Topic Meeting: Small Cell Lung Cancer

April 5-7, 2023  
New York, New York  
#SCLC23

### IASLC 2023 World Conference on Lung Cancer

September 9-12, 2023  
Singapore  
#WCLC23



INTERNATIONAL  
ASSOCIATION  
FOR THE STUDY  
OF LUNG CANCER  
Conquering Thoracic Cancers Worldwid

### IASLC.org/Meetings-Webinars

Scan the  
QR code for  
information  
on upcoming  
meetings and  
webinars.



### CONNECT WITH US

@IASLC

facebook.com/IASLC

@iaslungcancer

linkedin.com/IASLC

IASLC

\* Location and dates subject to change



# Join the IASLC Today!



Scan the QR code  
& enter

**LALCANewMember2023**

to receive half off  
membership dues  
for one year.



INTERNATIONAL  
ASSOCIATION  
FOR THE STUDY  
OF LUNG CANCER  
Conquering Thoracic Cancers Worldwide



IASLC  
Meeting  
Discounts

Patient  
Advocacy



Podcasts



Publications

ILCN



Networking



Research &  
Education



Scientific  
Expertise

IASLC  
Journals




Membership



ILC  
Foundation



Staging



Committees